Published in Nat Med on March 31, 2013
High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature (2016) 2.50
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function. Nucl Recept Signal (2015) 0.84
Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling. J Clin Invest (2015) 0.84
IGF1 Promotes Adipogenesis by a Lineage Bias of Endogenous Adipose Stem/Progenitor Cells. Stem Cells (2015) 0.81
Impaired musculoskeletal response to age and exercise in PPARβ(-/-) diabetic mice. Endocrinology (2014) 0.80
Minireview: nuclear receptor regulation of osteoclast and bone remodeling. Mol Endocrinol (2014) 0.80
Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget (2015) 0.79
The G32E functional variant reduces activity of PPARD by nuclear export and post-translational modification in pigs. PLoS One (2013) 0.78
Wnts' fashion statement: from body stature to dysplasia. Bonekey Rep (2014) 0.77
Molecular Pathways: Dietary Regulation of Stemness and Tumor Initiation by the PPAR-δ Pathway. Clin Cancer Res (2016) 0.76
Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice. Gene Ther (2015) 0.75
Human type H vessels are a sensitive biomarker of bone mass. Cell Death Dis (2017) 0.75
PPARδ preserves a high resistance to fatigue in the mouse medial gastrocnemius after spinal cord transection. Muscle Nerve (2015) 0.75
Regulation of Wnt/β-catenin signaling by herpesviruses. World J Virol (2016) 0.75
Heritability and genetic etiology of habitual physical activity: a twin study with objective measures. Genes Nutr (2014) 0.75
PPARβ/δ and its role in Wnt signaling and bone turnover. Bonekey Rep (2013) 0.75
Serotonin 2B receptor (5-HT2B R) signals through prostacyclin and PPAR-ß/δ in osteoblasts. PLoS One (2013) 0.75
A combination of biomolecules enhances expression of E-cadherin and peroxisome proliferator-activated receptor gene leading to increased cell proliferation in primary human meniscal cells: an in vitro study. Cytotechnology (2015) 0.75
PLCγ1 controls osteoclast numbers via CSF-1-dependent diacylglycerol/β-catenin/cyclinD1 pathway. J Biol Chem (2016) 0.75
Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair. Cell Res (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
PPARs and the complex journey to obesity. Nat Med (2004) 7.44
AMPK and PPARdelta agonists are exercise mimetics. Cell (2008) 6.39
Lrp5 functions in bone to regulate bone mass. Nat Med (2011) 5.33
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem (2005) 3.88
PPAR-gamma regulates osteoclastogenesis in mice. Nat Med (2007) 3.59
Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev (2002) 3.49
PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest (2006) 3.17
Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev (2005) 2.87
Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol (2010) 2.85
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol (2009) 2.50
IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One (2010) 1.92
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab (2010) 1.77
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol (2010) 1.72
COUP-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis. Proc Natl Acad Sci U S A (2009) 1.67
Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Gene Expr Patterns (2002) 1.61
Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem (2003) 1.49
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol (2006) 1.49
Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res (2012) 1.49
Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci (2007) 1.48
Wnt signaling in bone metabolism. J Bone Miner Metab (2009) 1.48
Skeletal consequences of thiazolidinedione therapy. Osteoporos Int (2007) 1.42
PPAR agonists modulate human osteoclast formation and activity in vitro. Bone (2006) 1.11
Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol (2007) 1.03
R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis Rheum (2010) 1.03
WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle (2004) 1.01
The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int (2008) 1.00
The role of PPARγ for the osteoblastic differentiation. J Endocrinol Invest (2010) 0.94
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol (2012) 0.89
The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells (2012) 0.84
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med (2006) 4.74
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res (2006) 3.01
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell (2011) 2.75
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2012) 2.66
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol (2002) 2.58
Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum (2010) 2.54
Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell (2002) 2.50
Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci U S A (2004) 2.46
Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol (2015) 2.39
A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37
Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature (2008) 2.30
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 2.29
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab (2006) 2.26
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J (2002) 2.15
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles. PLoS Biol (2012) 2.12
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med (2005) 2.06
Stem/progenitor cell-mediated de novo regeneration of dental pulp with newly deposited continuous layer of dentin in an in vivo model. Tissue Eng Part A (2010) 2.06
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity (2012) 2.06
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum (2009) 2.04
PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology (2006) 2.01
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol (2011) 1.94
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem (2007) 1.89
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microsc Res Tech (2005) 1.85
Detection of "Candidatus Neoehrlichia mikurensis" in two patients with severe febrile illnesses: evidence for a European sequence variant. J Clin Microbiol (2010) 1.82
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab (2010) 1.79
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: the randomized controlled senior fitness and prevention (SEFIP) study. Arch Intern Med (2010) 1.76
Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) (2011) 1.74
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Upstream and downstream targets of RUNX proteins. J Cell Biochem (2003) 1.71
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69
A new accurate and precise 3-D segmentation method for skeletal structures in volumetric CT data. IEEE Trans Med Imaging (2003) 1.68
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J (2009) 1.68
Exercise, body composition, and functional ability: a randomized controlled trial. Am J Prev Med (2010) 1.68
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum (2006) 1.64
Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum (2007) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development (2010) 1.61
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis. Arthritis Rheum (2013) 1.59
High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med (2002) 1.58
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis (2013) 1.57
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis (2011) 1.56
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
In vivo activation of PPAR target genes by RXR homodimers. EMBO J (2004) 1.53
Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) (2010) 1.53
The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol (2008) 1.52
Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med (2004) 1.51
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res (2012) 1.50
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol (2006) 1.49
Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J Bone Miner Res (2012) 1.49